http://news.excite.com/news/bw/011025/alpharx
Thu, Oct 25 12:03 PM EDT
RICHMOND HILL, Ontario (BW HealthWire)
- AlphaRx Inc. (OTCBB:AHRX) today announced a research study involving
ex-vivo and animal investigations to evaluate different proprietary anti-inflammatory
formulations for enhanced delivery effect on site inflammation, brain inflammation,
aging and neuroprotection. This study is a collaboration between AlphaRx,
NeuroProtection Inc. and the University Health Network, University of Toronto.
The principal research study investigator is Dr. Peter Carlen, Professor
of Medicine (Neurology) and Physiology at the University of Toronto, and
clinical Neurologist/scientist at the Toronto Western Research Institute
of the University Health Network.
The investigational compounds in
this study will include standard Non-Steroidal Anti-Inflammatory Drugs
(NSAIDs), in combination with AlphaRx's proprietary drug delivery vehicle,
and NeuroProtection Inc.'s proprietary membrane-permeable, calcium buffer
neuroprotective agents.
Part of this research will investigate
the neuroprotective activity of AlphaRx's two proprietary anti-inflammatory
compounds, code named ARX-2001 and ARX-2002, which have shown low toxicity,
rapid onset and prominent anti-inflammatory activity in previous animal
studies. The Company believes that these two compounds may have great neuroprotective
potential in acute nervous system disorders and injuries such as stroke,
as well as in chronic neurodegenerative disorders such as Alzheimer's disease,
Parkinson's disease, Huntington's disease, multiple sclerosis and epilepsy,
where many of the underlying mechanisms of neural tissue damage are similar.
About AlphaRx
AlphaRx Inc. is an emerging pharmaceutical
company that develops and markets innovative therapeutic products based
on its proprietary Bioadhesive Colloidal Dispersion (BCD) drug delivery
technology. AlphaRx's BCD technology improves the bioavailability and bioperformance
of poorly water-soluble drugs to provide improved medical benefits and
competitive commercial advantages.
About NeuroProtection Inc.
NeuroProtection Inc. (NPI) is a drug
development company specializing in the discovery and development of neuroprotective
compounds. NPI houses proprietary property in membrane-permeant calcium
buffers targeted at neuroprotection and aging. NeuroProtection Inc. also
provides novel drug screening services for the identification of neuroprotective
therapeutic candidates in compound libraries.
About Toronto Western Research
Institute
Toronto Western Research Institute
(TWRI) is one of the three research institutes comprising the University
Health Network (UHN). TWRI is home to the research programs associated
with the neural and visual sciences, musculoskeletal disease and urban
and community health priority programs at UHN. Neuroscientists at TWRI
explore the function of the nervous system as they develop treatments for
spinal cord injuries, cerebral ischemia, vascular malformations, brain
tumours, neurophthalmologic disorders and neurodegenerative diseases such
as Alzheimer's disease and Parkinson's disease.
FORWARD LOOKING STATEMENTS:
This release contains forward-looking
statements within the meaning and pursuant to the Safe Harbor provisions
of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties
that may individually or mutually impact the matters herein described,
including but not limited to product development and acceptance, manufacturing,
competition, regulatory and/or other factors, which are outside the control
of the Company.
©2001 At Home Corporation